Shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) dropped 8.3% on Wednesday . The company traded as low as $0.10 and last traded at $0.11. Approximately 21,957 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 55,127 shares. The stock had previously closed at $0.12.

Scopus BioPharma Stock Down 8.3 %

The business's fifty day moving average price is $0.17 and its two-hundred day moving average price is $0.28.

Institutional Investors Weigh In On Scopus BioPharma

An institutional investor recently raised its position in Scopus BioPharma stock. Renaissance Technologies LLC grew its stake in shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) by 438.4% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 112,523 shares of the company's stock after acquiring an additional 91,623 shares during the period. Renaissance Technologies LLC owned about 0.53% of Scopus BioPharma worth $78,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.16% of the company's stock.

Scopus BioPharma Company Profile

Scopus BioPharma Inc, a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.

See Also

• Get a free copy of the StockNews.com research report on Scopus BioPharma (SCPS)
• Procter & Gamble Earnings: A Gamble Worth Taking
• Stocks Slide, Economic Report Paints Gloomy Picture For Economy
• What does Nu Holdings Stock Have To Do With Warren Buffett?
• J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
• Is Intel Stock On The Verge Of Breaking Out?

Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.